Wagner Isabella V, Towne Caleb, Saade Marie C, Lentz P Connor, Rashedi Arianna, Vasu Pranav, Boopathiraj Nithya, Checo Leticia, Krambeer Chelsey, Miller Darby D, Dorairaj Syril
Department of Ophthalmology, Mayo Clinic, Jacksonville, Florida, United States of America.
Department of Nephrology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
J Curr Glaucoma Pract. 2024 Apr-Jun;18(2):79-85. doi: 10.5005/jp-journals-10078-1442. Epub 2024 Jul 10.
To review the published literature evaluating the safety and efficacy outcomes of canaloplasty performed in the treatment of glaucoma.
Canaloplasty is a nonpenetrating glaucoma procedure involving combined 360° circumnavigation and viscodilation of Schlemm's canal. The procedure may be performed under an ab externo (with tensioning suture) or ab-interno (conjunctiva-sparing) approach. Given the wide variety of glaucoma procedure types and approaches, further investigation into the role of canaloplasty in ophthalmological practice is warranted. The objectives of this narrative review are to synthesize the existing literature in order to investigate indications, safety and efficacy outcomes, and the optimal place of canaloplasty in glaucoma treatment and management.
A total of 60 articles were included in this review. Both ab externo and ab-interno canaloplasty (ABiC) were found to be significantly effective at reducing intraocular pressure (IOP) and glaucoma medication burdens in patients with mild-to-moderate open-angle glaucoma (OAG). These findings remained consistent regardless of phacoemulsification status. ABiC was found to exhibit a safety profile favorable compared to trabeculectomy and comparable to minimally invasive trabecular bypass implants.
Canaloplasty is a nonpenetrating surgical intervention that is highly effective in treating patients with mild-to-moderate OAG across a large variety of clinical scenarios.
These findings support the clinical use of canaloplasty in ophthalmological practice, clarify its patient profile, and compare procedural outcomes to other minimally invasive glaucoma surgery (MIGS) devices on the market.
Wagner IV, Towne C, Saade MC, A Review of Canaloplasty in the Treatment and Management of Glaucoma. J Curr Glaucoma Pract 2024;18(2):79-85.
回顾已发表的评估房角分离术治疗青光眼安全性和有效性结果的文献。
房角分离术是一种非穿透性青光眼手术，包括360°环形Schlemm管的环绕和粘弹性扩张。该手术可通过外路（带张紧缝线）或内路（保留结膜）方法进行。鉴于青光眼手术类型和方法的多样性，有必要进一步研究房角分离术在眼科实践中的作用。本叙述性综述的目的是综合现有文献，以研究其适应证、安全性和有效性结果，以及房角分离术在青光眼治疗和管理中的最佳地位。
本综述共纳入60篇文章。研究发现，外路和内路房角分离术（ABiC）在降低轻至中度开角型青光眼（OAG）患者的眼压（IOP）和青光眼药物负担方面均具有显著效果。无论晶状体超声乳化状态如何，这些结果均保持一致。与小梁切除术相比，ABiC显示出良好的安全性，与微创小梁旁路植入术相当。
房角分离术是一种非穿透性手术干预，在多种临床情况下对治疗轻至中度OAG患者非常有效。
这些发现支持房角分离术在眼科实践中的临床应用，明确其适用患者群体，并将手术结果与市场上其他微创青光眼手术（MIGS）设备进行比较。
瓦格纳四世、汤恩、萨德·麦克，《房角分离术治疗和管理青光眼的综述》。《当代青光眼实践杂志》2024年；18（2）：79 - 85。
